Evotec SE

EVO · XETRA

$1.50−$0.04 (−2.60%)TodayMarket closed ·
Prev close $1.54

About EVO

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Employees
4,526
Headquarters
Hamburg, Hamburg
Listed
Oct 11, 1999
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
evotec.com

Leadership

Evotec SE executives
NameTitleSince
Prof. Dr. Iris Loewfriedrich—2014
Christian Wojczewski——
Roland Sackers—2019
Laetitia Rouxel——
Aurelie Dalbiez——
Cord Dohrmann——
Camilla Languille——
Constanze Ulmer-Eilfort——
Duncan Mchale——
Wesley Wheeler——
Volker Braun—2021

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.